Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988282 | 1.00 | L3MBTL1 (0.62) | L3MBTL1MEN1KMT2AALDH1A1MPO | |
| SCHEMBL9975264 | 1.00 | L3MBTL1 (0.62) | L3MBTL1MEN1KMT2AALDH1A1MPO | |
| SCHEMBL2988309 | 0.85 | USP2 (0.67) | L3MBTL1MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL2988300 | 0.85 | USP2 (0.67) | L3MBTL1MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL2992611 | 0.85 | USP2 (0.67) | L3MBTL1MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL2988318 | 0.85 | USP2 (0.67) | L3MBTL1MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL2992609 | 0.85 | USP2 (0.67) | L3MBTL1MEN1KMT2AALDH1A1NPC1 | |
| Crotoniazide SCHEMBL2997623 | 0.83 | USP2 (0.65) | L3MBTL1MEN1KMT2AALDH1A1MPO | |
| Crotoniazide SCHEMBL2997626 | 0.83 | USP2 (0.65) | L3MBTL1MEN1KMT2AALDH1A1MPO | |
| Crotoniazide SCHEMBL2109838 | 0.83 | USP2 (0.65) | L3MBTL1MEN1KMT2AALDH1A1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| EP-2068873-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | Pharma 2100 (DK) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008031440-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | PHARMA 2100 (DK) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | L3MBTL1 1229/4885MEN1 4193/4885KMT2A 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.